Omega-3 Supplements Tested in Pregnant Women Living With HIV
Tests omega-3 supplements against a placebo in pregnant women with HIV.
Plain-language title generated from the registry record
Registry title: Effect of Omega-3 Supplementation on Pregnant Outcomes and Inflammation Markers of Women Infected With HIV Using Antiretroviral Therapy
Key facts
- Where
- Mexico City, MexicoSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for pregnant women with a single pregnancy, between 20 and 29 weeks along. The record's title and summary describe them as living with HIV and on antiretroviral therapy.
- Age
- 18 years or older.
- Sex
- Women only.
- Disease stage
- Pregnancy of 20 to 29 weeks, counted from the first day of the last period. Single pregnancy only.
Main reasons for not taking part
- Pregnancy further along than 29 weeks
- Gestational diabetes or preeclampsia
- Smoking and/or drug use
- Fish allergy
This trial only enrols pregnant participants. The registry sentence this rests on: Pregnant women
Read by machine on 9 November 2026.
Where in Mexico
- Instituto Nacional de PerinatologiaMexico City, MexicoNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes
- Trial code
- NCT06971445
- Record updated
- 6 November 2026
- Original description
This clinical trial aims to determine the effect of PUFA-n3 supplementation on birth weight, gestational length, and plasma inflammatory markers in pregnant women with HIV who are on antiretroviral therapy. The key questions this study seeks to answer are:Read full original descriptionShow less
Effect of Polyunsaturated Fatty Acids Omega-3 Supplementation on Pregnancy Outcomes and Inflammation Markers in Pregnant Women HIV+, With Antiretroviral Therapy, Randomized Clinical Trial.
This clinical trial aims to determine the effect of PUFA-n3 supplementation on birth weight, gestational length, and plasma inflammatory markers in pregnant women with HIV who are on antiretroviral therapy. The key questions this study seeks to answer are:
1. Will the neonates of HIV-positive women who received 1280 mg of PUFA-n3 supplementation during pregnancy have higher birth weights and longer gestation periods compared to the neonates of HIV-positive women who received a placebo? 2. Will the inflammatory markers in HIV-positive women who received 1280 mg of PUFA-n3 during pregnancy differ from those of HIV-positive women who received a placebo?
Researchers will compare the effects of 1280 mg of PUFA-n3 supplementation against a placebo (olive oil) to determine if the supplement can increase birth weight, gestational length, and attenuate the inflammation.
Participants in the study will:
* Take a prenatal multivitamin that includes 300 mg of PUFA-n3 * Take either 1280 mg of PUFA-n3 or a placebo daily for 8 weeks, starting from a gestational age of 20-29 weeks. * Visit the hospital at the beginning of the study and again 8 weeks later for blood sampling. Additionally, they will have follow-up visits every 2 weeks to monitor gestational weight gain and dietary intake. * Keep a diary to register their supplement intake and record any side effects.
Inclusion: Pregnant women; Single pregnancy; Gestational age from 20 to 29 weeks since the first day of the last menstrual period; Agree to participate in the study.
Exclusion: Smoking and/or drug use during the invitation to participate in the study; With diagnosis of gestational diabetes or preeclampsia; Fish allergy; Gestational age more than 29 weeks.